Louise Donnelly is Professor of Respiratory Cell Biology, within the Section of Airway Disease at the NHLI. She obtained her BSc in Biochemistry from the University of Bath and subsequently a PhD in Biochemistry from the University of Cardiff. This was followed by a post-doctoral position in cell signaling at the Royal Postgraduate Medical School (now part of Imperial College London) prior to working at the NHLI.
Since 1995, Professor Donnelly has worked in the field of respiratory cell biology with a particular interest in the cellular profile in inflammatory lung diseases including asthma and COPD. Her research has focussed upon how inflammatory cells are altered in the disease state and the investigation of novel therapeutic strategies. To this end, she has established a number of human primary cell systems to investigate mechanisms of aberrant inflammation. She has published extensively and has presented both nationally and internationally as well as acting as an editor for Current Respiratory Medicine Reviews.
Professor Donnelly is currently Director of the Respiratory Science BSc and is involved in respiratory teaching on the undergraduate MBSS course. In 2009, Professor Donnelly received a Rector's Award for Research Supervision and in 2012 a Rector's Award for Pastoral Care.
Professor Donnelly has been a member of the British Association of Lung Research (BALR) committee for several years and is the current chair of the BALR. She is currently a member of the British Lung Foundation Scientific Committee and the European Respiratory Society Evaluation Committee
et al., 2017, Catalog of Differentially Expressed Long Non-Coding RNA following Activation of Human and Mouse Innate Immune Response, Frontiers in Immunology, Vol:8, ISSN:1664-3224
et al., 2017, Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD, American Journal of Physiology-lung Cellular and Molecular Physiology, Vol:313, ISSN:1040-0605, Pages:L230-L239
et al., 2017, Downregulation of MicroRNA-126 Augments DNA Damage Response in Cigarette Smokers and COPD Patients., Am J Respir Crit Care Med
et al., 2017, Isorhapontigenin, a bioavailable dietary polyphenol, suppresses airway epithelial cell inflammation through a corticosteroid-independent mechanism, British Journal of Pharmacology, Vol:174, ISSN:0007-1188, Pages:2043-2059
, Administration of Resveratrol to Treat Inflammatory Respiratory Disorders, US, 09/694, 108